Ticker > Company >

Supriya Lifescience share price

Supriya Lifescience Ltd.

NSE: SUPRIYA BSE: 543434 SECTOR: Pharmaceuticals & Drugs  234k   484   91

703.00
+13.85 (2.01%)
BSE: 21 Nov 04:00 PM

Price Summary

Today's High

₹ 708.9

Today's Low

₹ 666.8

52 Week High

₹ 704.35

52 Week Low

₹ 245.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5657.94 Cr.

Enterprise Value

5582.98 Cr.

No. of Shares

8.05 Cr.

P/E

35.92

P/B

6.25

Face Value

₹ 2

Div. Yield

0.11 %

Book Value (TTM)

₹  112.56

CASH

74.96 Cr.

DEBT

0 Cr.

Promoter Holding

68.3 %

EPS (TTM)

₹  19.57

Sales Growth

23.74%

ROE

15.73 %

ROCE

22.31%

Profit Growth

32.56 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year23.74%
3 Year13.39%
5 Year15.47%

Profit Growth

1 Year32.56%
3 Year-1.22%
5 Year24.75%

ROE%

1 Year15.73%
3 Year21.24%
5 Year36.66%

ROCE %

1 Year22.31%
3 Year28.12%
5 Year38.83%

Debt/Equity

0

Price to Cash Flow

49.93

Interest Cover Ratio

33.1791

CFO/PAT (5 Yr. Avg.)

0.748802836976067

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 68.30 0.00
Jun 2024 68.30 0.00
Mar 2024 68.30 0.00
Dec 2023 68.30 0.00
Sep 2023 68.30 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 16.625 Cr.
  • Company has been maintaining healthy ROE of 21.2423092929279% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.1204945228842% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 33.1791.
  • The Company has been maintaining an effective average operating margins of 31.1848267744753% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 10.2042 days.
  • Company has a healthy liquidity position with current ratio of 5.0328.
  • The company has a high promoter holding of 68.3%.

 Limitations

  • The company has shown a poor profit growth of -1.22289087810298% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.3912326197026% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 140.1 140.07 158.18 160.63 166.1
Total Expenditure 108.34 98.59 102.68 98.08 101.39
Operating Profit 31.75 41.49 55.5 62.54 64.72
Other Income 2.47 3.07 2.19 2.22 2.52
Interest 0.46 0.49 0.6 0.34 0.43
Depreciation 3.98 3.96 3.91 4.66 4.74
Exceptional Items 0 0 0 0 0
Profit Before Tax 29.78 40.1 53.17 59.78 62.06
Tax 5.89 10.31 16.24 15.13 15.92
Profit After Tax 23.88 29.79 36.93 44.64 46.15
Adjusted EPS (Rs) 2.97 3.7 4.59 5.55 5.73

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 311.64 391.22 530.05 460.94 570.37
Total Expenditure 213.26 218.07 316.06 332.5 394.68
Operating Profit 98.38 173.15 213.98 128.44 175.69
Other Income 11.07 5.01 7.58 9.94 10.96
Interest 6.85 4.08 4.2 3.08 5.15
Depreciation 6.38 6.76 10.12 11.82 15.81
Exceptional Items 0 0 0 0 0
Profit Before Tax 96.23 167.31 207.25 123.49 165.69
Tax 22.82 43.72 55.44 33.63 46.58
Net Profit 73.4 123.59 151.81 89.86 119.11
Adjusted EPS (Rs.) 10.03 16.89 18.86 11.16 14.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 14.64 14.64 16.1 16.1 16.1
Total Reserves 134.56 253.95 599.59 683.36 799.27
Borrowings 2.39 0 0 0 0
Other N/C liabilities 29.46 30.86 19.38 25.04 28.98
Current liabilities 155.39 146.02 99.7 95.78 79.57
Total Liabilities 336.43 445.47 734.76 820.28 923.92
Assets
Net Block 97.99 100.04 189.77 261.54 310.13
Capital WIP 40.21 78.79 43.41 67.63 148.83
Intangible WIP 0 0 0 0 0
Investments 0.05 0.05 0.05 25.3 63.8
Loans & Advances 0.18 1.13 3.98 0.93 0.68
Other N/C Assets 0 0 0 0 0
Current Assets 197.99 265.46 497.54 464.89 400.48
Total Assets 336.43 445.47 734.76 820.28 923.92
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 96.23 167.31 207.25 123.49 165.69
Adjustment 10.24 5.39 6.87 4.61 2.4
Changes in Assets & Liabilities 36.6 -66.82 -104.35 -33.82 -17.14
Tax Paid -27.01 -29.99 -60.96 -30.68 -37.65
Operating Cash Flow 116.06 75.89 48.8 63.61 113.31
Investing Cash Flow -24.53 -46.8 -59.82 -123.65 -173.58
Financing Cash Flow -29.23 -14.52 149.65 -10.28 -22.36
Net Cash Flow 62.31 14.57 138.63 -70.32 -82.63

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 68.30 68.30 68.30 68.30 68.30
saloni satish wagh 0.04 0.22 0.13 0.13 0.13
satish waman wagh 67.64 67.64 67.64 67.64 67.64
shivani satish wagh 0.04 0.04 0.13 0.13 0.13
smita satish wagh 0.40 0.40 0.40 0.40 0.40
asha waman wagh 0.18 - - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 31.70 31.70 31.70 31.70 31.70
aditya birla sun life ins... 3.68 3.60 3.50 3.61 3.02
cohesion mk best ideas su... 1.99 1.99 1.99 1.99 1.99
hornbill orchid india fun... 1.89 1.89 1.89 1.89 1.89
llp 0.06 0.25 0.28 - 0.22
nippon life india trustee... 1.71 - - - -

Ratings & Research Reports

Company Presentations

Company News

Supriya Lifescience submits analyst meet intimation 7 Nov, 4:40 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience informs about board meeting 21 Oct, 12:44 PM Supriya Lifescience informs about compliance certificate 9 Oct, 1:25 PM Supriya Lifescience informs about outcome of AGM 30 Sep, 5:00 PM Supriya Lifescience informs about analyst meet 11 Sep, 12:16 PM Supriya Lifescience informs about analyst meet 9 Sep, 5:18 PM Supriya Lifescience informs about transcript of earnings call 19 Aug, 12:57 PM Supriya Lifescience’s net profit rises 57% in Q1 10 Aug, 3:12 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience informs about earnings call 5 Aug, 11:50 AM Supriya Lifescience submits analyst meet intimation 7 Jun, 4:45 PM Supriya Lifescience - Quaterly Results 28 May, 6:31 PM Supriya Lifescience - Quaterly Results 28 May, 6:31 PM Supriya Lifescience informs about annual secretarial compliance report 27 May, 3:04 PM Supriya Lifescience informs about disclosure 24 Apr, 2:50 PM Supriya Lifescience submits analyst meet intimation 6 Mar, 5:02 PM Supriya Lifescience informs about conference call 5 Mar, 2:53 PM Supriya Lifescience informs about analyst meet 5 Mar, 10:38 AM Supriya Lifescience informs about disclosure 29 Feb, 10:57 AM Supriya Lifescience informs about analyst meet 23 Feb, 2:48 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience gets GMP certification from ANVISA Brazil 5 Jan, 3:12 PM Supriya Lifescience informs about trading window closure 28 Dec, 12:07 PM Supriya Lifescience - Quaterly Results 7 Nov, 4:55 PM Supriya Lifescience - Quaterly Results 7 Nov, 4:55 PM Supriya Lifescience collaborates with Kalinga Institute of Industrial Technology 23 Oct, 3:20 PM Supriya Lifescience submits analyst meet intimation 26 Sep, 12:55 PM Supriya Lifescience submits analyst meet 14 Sep, 4:45 PM Supriya Lifescience informs about analyst meet 11 Sep, 11:09 AM Supriya Lifescience informs about record date and book closure date 5 Sep, 5:06 PM Supriya Lifescience submits analyst meet intimation 17 Aug, 4:43 PM Supriya Lifescience informs about press release 4 Aug, 10:27 AM Supriya Lifescience - Quaterly Results 3 Aug, 5:29 PM Supriya Lifescience - Quaterly Results 3 Aug, 5:29 PM Supriya Lifescience - Quaterly Results 3 Aug, 5:29 PM Supriya Lifescience collaborates with Plasma Nutrition 2 Aug, 3:45 PM Supriya Lifescience informs about earnings call 28 Jul, 12:24 PM Supriya Lifescience submits board meeting intimation 27 Jul, 4:18 PM Supriya Lifescience informs updates 5 Jul, 12:04 PM Supriya Lifescience informs about newspaper advertisement 1 Jul, 3:09 PM Supriya Lifescience informs about closure of trading window 28 Jun, 2:43 PM Supriya Lifescience informs about informs about investor meeting 22 Jun, 10:25 AM Supriya Lifescience informs about transcript of earnings call 2 Jun, 12:18 PM

Supriya Lifescience Stock Price Analysis and Quick Research Report. Is Supriya Lifescience an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Supriya Lifescience and its performance over the period of time. Supriya Lifescience stock price today is Rs 703.45.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Supriya Lifescience cash from the operating activity was Rs 113.307 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Supriya Lifescience has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Supriya Lifescience , the EPS growth was 32.5597 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Supriya Lifescience has OPM of 30.803513508775 % which is a good sign for profitability.
     
  • ROE: Supriya Lifescience have a average ROE of 15.7264 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Supriya Lifescience is Rs 703.45. One can use valuation calculators of ticker to know if Supriya Lifescience share price is undervalued or overvalued.
Last Updated on:
Brief about Supriya Lifescience

Supriya Lifescience Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Supriya Lifescience Ltd. is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality generic drugs. With a strong presence in both domestic and international markets, the company has established itself as a trusted provider of affordable healthcare solutions. Supriya Lifescience offers a wide range of products across various therapeutic categories, including cardiovascular, gastrointestinal, respiratory, and women's health. With a commitment to innovation and customer satisfaction, the company has earned a reputation for delivering superior healthcare products.

Supriya Lifescience Ltd. - Share Price

Supriya Lifescience Ltd.'s share price is an important indicator for investors interested in the company. The share price reflects the market's perception of the company's value and future prospects. It is influenced by various factors, including financial performance, industry trends, and market sentiment. Investors can track the share price through our website's stock analysis page. We provide real-time and historical share price data, along with charts and tools to help investors analyze the stock's performance.

Supriya Lifescience Ltd. - Balance Sheet

The balance sheet of Supriya Lifescience Ltd. provides a snapshot of the company's financial position at a given point in time. It reveals the company's assets, liabilities, and shareholders' equity. The balance sheet helps investors assess the company's liquidity, solvency, and ability to generate returns. Using our pre-built screening tools, investors can analyze Supriya Lifescience's balance sheet and identify key financial ratios and indicators. Additionally, our premium features allow for fair value calculations using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Supriya Lifescience Ltd. - Annual Report

The annual report of Supriya Lifescience Ltd. provides a comprehensive overview of the company's performance, strategy, and future prospects. It contains important information such as financial statements, management's discussion and analysis, corporate governance practices, and sustainability initiatives. As part of our commitment to transparency, we make Supriya Lifescience's annual reports available for download on our website. Investors can access these reports to gain deeper insights into the company's operations and make informed investment decisions.

Supriya Lifescience Ltd. - Dividend

Dividends are an important consideration for long-term stock investors. They represent a portion of a company's earnings that is distributed to its shareholders. Supriya Lifescience Ltd. has a track record of consistently sharing its profits with shareholders through dividends. Investors can stay updated on the company's dividend payouts through our stock analysis page. Additionally, our website provides access to research reports and credit ratings that evaluate Supriya Lifescience's dividend payout history and financial stability.

Supriya Lifescience Ltd. - Quarterly Result

Supriya Lifescience Ltd.'s quarterly results provide investors with insights into the company's financial performance and operational efficiency. By monitoring the quarterly results, investors can track the company's progress, identify trends, and assess its ability to generate sustainable earnings. Our website offers downloadable materials such as con-call transcripts and investor presentations that provide in-depth analysis and commentary on Supriya Lifescience's quarterly results.

Supriya Lifescience Ltd. - Stock Price

Supriya Lifescience Ltd.'s stock price reflects the market's valuation of the company at any given time. It is influenced by various factors such as financial performance, industry trends, market sentiment, and economic conditions. Our stock analysis page provides investors with real-time and historical stock price data, along with interactive price charts. Investors can utilize our pre-built screening tools to analyze Supriya Lifescience's stock price and identify potential investment opportunities.

Supriya Lifescience Ltd. - Price Chart

Analyzing price charts is an essential tool for technical analysis and understanding Supriya Lifescience Ltd.'s stock price movements. Our website offers interactive price charts that allow investors to track historical price data, identify patterns, and determine potential entry or exit points. By using our pre-built screening tools in combination with price charts, investors can gain valuable insights into Supriya Lifescience's stock price behavior.

Supriya Lifescience Ltd. - News

Staying informed about the latest news and developments in Supriya Lifescience Ltd. is crucial for investors. Our stock analysis page provides a dedicated news section that covers relevant industry news, company announcements, regulatory updates, and market insights. Investors can access our website for the most up-to-date news that can impact Supriya Lifescience's stock performance.

Supriya Lifescience Ltd. - Concall Transcripts

Concall transcripts provide a detailed account of Supriya Lifescience Ltd.'s conference call discussions with analysts and investors. These transcripts offer insights into the company's strategy, financial performance, future outlook, and responses to pertinent questions. As part of our commitment to providing comprehensive information, we make these transcripts available for download on our website. Investors can access them to gain a deeper understanding of Supriya Lifescience's operations and investment prospects.

Supriya Lifescience Ltd. - Investor Presentations

Investor presentations are a valuable resource for understanding Supriya Lifescience Ltd.'s business model, growth strategy, and competitive advantages. These presentations often include financial data, operational highlights, and upcoming initiatives. At our website, we provide downloadable investor presentations to provide investors with a comprehensive overview of Supriya Lifescience's investment potential.

Supriya Lifescience Ltd. - Promoters

Promoters play a critical role in shaping the direction and performance of Supriya Lifescience Ltd. Promoters are individuals or entities that have founded or established the company and hold a significant stake in its equity. Understanding the promoters' background, experience, and ownership is crucial for investors evaluating Supriya Lifescience's long-term prospects. Our stock analysis page provides detailed information about Supriya Lifescience's promoters to help investors make informed decisions.

Supriya Lifescience Ltd. - Shareholders

Shareholders are the owners of Supriya Lifescience Ltd. and have a vested interest in the company's growth and profitability. Identifying the major shareholders and their stake in the company provides insights into the ownership structure and potential influence on decision-making. Our website offers information about Supriya Lifescience's major shareholders, allowing investors to gauge the level of institutional and retail investor participation in the company.

Please note that this content is focused on providing stock analysis information and does not include any financial data or numbers about the stock.

Read More
X